CN1528315A - 治疗糖皮质素功能失调相关性精神病的方法 - Google Patents

治疗糖皮质素功能失调相关性精神病的方法 Download PDF

Info

Publication number
CN1528315A
CN1528315A CNA200410039908XA CN200410039908A CN1528315A CN 1528315 A CN1528315 A CN 1528315A CN A200410039908X A CNA200410039908X A CN A200410039908XA CN 200410039908 A CN200410039908 A CN 200410039908A CN 1528315 A CN1528315 A CN 1528315A
Authority
CN
China
Prior art keywords
psychosis
psychotic
antagonist
glucocorticoid
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200410039908XA
Other languages
English (en)
Chinese (zh)
Inventor
A��F��ɳ�IJ���
A·F·沙茨伯格
��˹��ŵ��
J·K·贝拉诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN1528315A publication Critical patent/CN1528315A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA200410039908XA 1997-10-06 1998-10-05 治疗糖皮质素功能失调相关性精神病的方法 Pending CN1528315A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6097397P 1997-10-06 1997-10-06
US60/060,973 1997-10-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB988097923A Division CN1187053C (zh) 1997-10-06 1998-10-05 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2006101003657A Division CN1919199A (zh) 1997-10-06 1998-10-05 治疗糖皮质素功能失调相关性精神病的方法

Publications (1)

Publication Number Publication Date
CN1528315A true CN1528315A (zh) 2004-09-15

Family

ID=22032889

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA200410039908XA Pending CN1528315A (zh) 1997-10-06 1998-10-05 治疗糖皮质素功能失调相关性精神病的方法
CNA2006101003657A Pending CN1919199A (zh) 1997-10-06 1998-10-05 治疗糖皮质素功能失调相关性精神病的方法
CNB988097923A Expired - Fee Related CN1187053C (zh) 1997-10-06 1998-10-05 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNA2006101003657A Pending CN1919199A (zh) 1997-10-06 1998-10-05 治疗糖皮质素功能失调相关性精神病的方法
CNB988097923A Expired - Fee Related CN1187053C (zh) 1997-10-06 1998-10-05 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途

Country Status (17)

Country Link
US (2) US6150349A (https=)
EP (1) EP1023074B1 (https=)
JP (3) JP2001518509A (https=)
KR (2) KR100840957B1 (https=)
CN (3) CN1528315A (https=)
AT (1) ATE332696T1 (https=)
AU (1) AU747956B2 (https=)
CA (1) CA2302586C (https=)
CY (1) CY1106330T1 (https=)
DE (1) DE69835225T2 (https=)
DK (1) DK1023074T3 (https=)
ES (1) ES2268792T3 (https=)
IL (2) IL135469A0 (https=)
NO (1) NO327233B1 (https=)
NZ (1) NZ503250A (https=)
PT (1) PT1023074E (https=)
WO (1) WO1999017779A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063526A1 (fr) * 2004-12-15 2006-06-22 Shanghai Three-Alliance Biotechnologies Co., Ltd. Utilisation de la cymipristone pour le traitement de la depression

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903146A1 (en) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
GB9915625D0 (en) * 1999-07-02 1999-09-01 Cortendo Ab Method
US6620802B1 (en) * 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
SI1325022T1 (sl) * 2000-09-18 2007-04-30 Applied Research Systems Metoda za pripravo 21-hidroksi-6,19-oksidoprogesterona (21oh-6op)
CN1820756A (zh) * 2001-03-23 2006-08-23 科塞普特治疗公司 使用糖皮质激素受体特效拮抗剂治疗压力症的方法
US7163934B2 (en) 2001-05-04 2007-01-16 Corcept Therapeutics, Inc. Methods for treating delirium glucocorticoid receptor-specific antagonists
DE60238671D1 (de) * 2001-05-04 2011-02-03 Corcept Therapeutics Inc Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von delirium
AU2002319665B2 (en) 2001-07-23 2006-09-21 Corcept Therapeutics, Inc. Methods for preventing antipsychotic-induced weight gain
IL160649A0 (en) * 2001-08-31 2004-07-25 Corcept Therapeutics Inc Methods for inhibiting cognitive deterioration in adults with down syndrome
KR20050038580A (ko) * 2001-10-26 2005-04-27 악조 노벨 엔.브이. 주요 우울 장애의 치료에 사용되는(11β,17β)-11-(1,3-벤조디옥솔-5-일)-17-히드록시-17-(1-프로피닐)-에스트라-4,9-디엔-3-온의 용도
WO2003043640A2 (en) * 2001-11-23 2003-05-30 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
US7326697B2 (en) * 2002-04-29 2008-02-05 Corcept Therapeutics, Inc. Methods for increasing the therapeutic response to electroconvulsive therapy
CN1665515A (zh) * 2002-07-02 2005-09-07 科塞普特治疗公司 治疗与干扰素α治疗相关的精神病的方法
WO2004054587A1 (en) * 2002-12-18 2004-07-01 University Of Zurich Treatment of neuro-psychiatric disorders
EP1599208A4 (en) * 2003-02-04 2007-09-12 Corcept Therapeutics Inc ANTIGLUCOCORTICOIDES FOR THE TREATMENT OF POSTPARTAL PSYCHOSIS
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
US20090156565A1 (en) * 2004-12-03 2009-06-18 The Children's Hospital Of Philadelphia Composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug
US20060229505A1 (en) * 2005-04-08 2006-10-12 Mundt James C Method and system for facilitating respondent identification with experiential scaling anchors to improve self-evaluation of clinical treatment efficacy
JP2009535430A (ja) * 2006-05-02 2009-10-01 コーセプト セラピューティクス， インコーポレイテッド Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用
EP1987814A1 (en) * 2007-04-30 2008-11-05 Exelgyn Mifepristone pharmaceutical compositions and their methods of preparation
RU2327448C1 (ru) 2007-05-23 2008-06-27 Виктор Иванович Рощин Средство для лечения зависимости от этилового спирта и/или от наркотиков, фармацевтическая композиция, активный ингредиент фармацевтической композиции, способ лечения зависимости от этилового спирта и/или от наркотиков для лечения психосоматических и неврологических осложнений у алкоголиков и/или наркоманов
CA2698172C (en) * 2007-06-15 2014-02-18 Cook, Kevin M. Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
EP2576582B1 (en) * 2010-05-26 2019-09-18 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
EP2671086B1 (en) 2011-02-03 2018-04-25 Pop Test Oncology LLC System and method for diagnosis and treatment
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
CN107530435A (zh) * 2015-03-02 2018-01-02 科赛普特治疗学股份有限公司 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
PH12017502099B1 (en) * 2015-05-18 2023-08-30 Corcept Therapeutics Inc Methods for diagnosing and assessing treatment for cushing's syndrome
US11793448B2 (en) * 2016-10-21 2023-10-24 Citizen Watch Co., Ltd. Detection device
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
PH12022551430A1 (en) 2019-12-11 2023-11-20 Corcept Therapeutics Inc Methods of treating antipsychotic-induced weight gain with miricorilant
WO2023033900A1 (en) 2021-09-06 2023-03-09 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5348729A (en) * 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
FR2739029B1 (fr) * 1995-09-21 1997-11-21 Roussel Uclaf Nouvelle application therapeutique des composes antimineralo-corticoides
DE69737791D1 (de) * 1996-04-09 2007-07-19 Univ Edinburgh Verwendung von 7-alpha-substituierten steroiden zur behandlung von neuropsychiatrischen erkrankungen
FR2757400B1 (fr) * 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063526A1 (fr) * 2004-12-15 2006-06-22 Shanghai Three-Alliance Biotechnologies Co., Ltd. Utilisation de la cymipristone pour le traitement de la depression

Also Published As

Publication number Publication date
NZ503250A (en) 2001-09-28
PT1023074E (pt) 2006-12-29
JP2009051858A (ja) 2009-03-12
CN1187053C (zh) 2005-02-02
JP2001518509A (ja) 2001-10-16
WO1999017779A1 (en) 1999-04-15
NO20001744L (no) 2000-04-05
DE69835225D1 (de) 2006-08-24
KR20010024431A (ko) 2001-03-26
CA2302586A1 (en) 1999-04-15
AU747956B2 (en) 2002-05-30
JP5180125B2 (ja) 2013-04-10
NO327233B1 (no) 2009-05-18
EP1023074A1 (en) 2000-08-02
EP1023074B1 (en) 2006-07-12
CN1919199A (zh) 2007-02-28
KR100840957B1 (ko) 2008-06-24
IL135469A (en) 2007-03-08
CY1106330T1 (el) 2011-10-12
US6150349A (en) 2000-11-21
IL135469A0 (en) 2001-05-20
ATE332696T1 (de) 2006-08-15
KR100804558B1 (ko) 2008-02-20
CN1272788A (zh) 2000-11-08
US6362173B1 (en) 2002-03-26
DK1023074T3 (da) 2006-11-06
CA2302586C (en) 2008-06-10
DE69835225T2 (de) 2007-07-05
JP2009132743A (ja) 2009-06-18
KR20070032822A (ko) 2007-03-22
ES2268792T3 (es) 2007-03-16
AU9683298A (en) 1999-04-27
NO20001744D0 (no) 2000-04-05

Similar Documents

Publication Publication Date Title
CN1528315A (zh) 治疗糖皮质素功能失调相关性精神病的方法
CN1130200C (zh) 用于治疗痴呆的糖皮质激素受体拮抗剂
JP2009102343A (ja) ダウン症候群を有する成人において認知低下を阻害する方法
CN1820756A (zh) 使用糖皮质激素受体特效拮抗剂治疗压力症的方法
JP2005526843A (ja) 電気痙攣療法（「ｅｃｔ」）に対する治療応答を増大させるための方法
EP2694065B1 (en) Composition for treating hypoactive sexual desire disorder
BR112015002687A2 (pt) regimes de tratamento
US20240408086A1 (en) Use of luvadaxistat for the treatment of cognitive impairment
US20180289655A1 (en) Methods and Compositions for the Intravenous Administration of Fumarates for the Treatment of Neurological Diseases
WO2008047983A1 (en) Composition for preventing and treating inflammatory bowel diseases
HK1104214A (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
CN121221609A (zh) 一种葡萄糖神经酰胺合成酶激活剂在制备预防和/或治疗焦虑的药物中的用途
JP2005512949A (ja) グルココルチコイドレセプターに特異的なアンタゴニストを使用して、せん妄を処置する方法
CN117580576A (zh) Luvadaxistat用于治疗认知损害的用途
Lunenfeld PL1–01
CN1853638A (zh) 使用糖皮质激素受体特效拮抗剂治疗谵妄症的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication